New Research Signals Weight Gain After Stopping GLP-1 Drugs is Not Inevitable

The rapid rise of GLP-1 weight loss drugs has revolutionized the way that people approach losing weight. While the medications are hailed as miracle drugs by many people, several studies have revealed that patients may rapidly regain the weight loss after stopping the treatment. However, a recent study is giving those who stop the medications hope that the regain is not inevitable. Here is a look at the surprising results of this study.

New Study Offers Optimism About Weight Management After GLP-1 Treatments

Millions of Americans have jumped on the injectable GLP-1 medication train in recent months. Drugs such as Ozempic, Zepbound, and Wegovy have proved to be highly effective in helping people to lose weight. Unfortunately for those who have found success with the drugs, numerous clinical trials have signaled that many patients experience a rebound effect when stopping the medication. The analysis of these past studies revealed that the weight piled back on nearly four times faster than after lifestyle changes, such as quitting an exercise routine or diet. These results were the same regardless of how many pounds had been lost.

While these results are certainly discouraging for those hoping to lose the weight and keep it off without the constant reliance on the drug, a new study from the Cleveland Clinic is offering a little bit of hope. The results of the study were recently published in the journal Diabetes, Obesity, and Metabolism, providing a different perspective on what happens to the body when a patient stops using the GLP-1 injections.

The researchers with the Cleveland Clinic looked at almost 8,000 adults living in Florida and Ohio on the GLP-1 drugs. All of the patients had used either semaglutide or tirzepatide for three to 12 months before discontinuing the use. The study examined what they called the "real-world" outcomes of patients switching from one medication to another.

In general, these patients did not see a meaningful weight regain during the year immediately following the end of the GLP-1 treatment. Those patients who had used the drugs specifically to treat obesity had lost an average of 8.4% of their body weight while on the drugs. These participants had regained just 0.5% of this weight after stopping the drug, on average.

Diving Into the Data

Dr. Hamlet Gasoyan, lead author of the study, said that the data indicates that many patients who stop using semaglutide or tirzepatide and restart it or switch to a similar obesity treatment regain less weight than what was presented in previous randomized trials. This data suggests that patients in clinical trials who regain weight do so because they do not have an alternative treatment to fall back on.

Approximately 27% of patients in the study transitioned to different types of obesity medications. Similarly, another 20% went back to their original medication once the side effects or insurance problems were resolved. The most common reasons cited by people who stop the treatment are muscle loss, dehydration, nausea, vomiting, constipation, diarrhea, bloating, headaches, thinning hair, and fatigue. Older patients are the most vulnerable to gastrointestinal sensitivities while on the drugs.

An additional 14% of the participants in the Cleveland Clinic study transitioned to non-medical lifestyle modification programs under the direction of exercise trainers and dietitians. The personalized approach to keeping the pounds away could be a key to long-term success.

Those patients who were able to maintain their weight were more engaged with medical providers and the healthcare system. Researchers said that these patients leaned on tools such as alternative prescriptions or other types of support in an effort to keep the weight off.

The researchers acknowledged some limitations to the study. For example, while adult patients in both Ohio and Florida were included in the study, different patient characteristics vary throughout the country. In addition, various healthcare systems also employ different protocols, which could mitigate the generalizability of the data.

It is also possible that some of the reported weight loss could be associated with other interventions not captured by the study. So while the results offer a bit of optimism about the future of long-term weight loss drug use, the data should be taken with a grain of salt. It is clear that more research is needed as the medical field figures out how patients can lose weight and keep it off over time.

Looking for stories that inform and engage? From breaking headlines to fresh perspectives, WaveNewsToday has more to explore. Ride the wave of what’s next.